Publication|Articles|November 19, 2026

Supplements

  • Practical Considerations for Stroke Prevention Across the Continuum

A Pharmacist's Checklist for Coordinating Care

Fact checked by: Nicole Canfora Lupo
Listen
0:00 / 0:00

Key Takeaways

  • Comprehensive regimen mapping should identify duplicate anticoagulants and anticoagulant–antiplatelet combinations lacking indication, which elevate bleeding risk without thrombosis benefit in most secondary stroke prevention scenarios.
  • DOAC dose validation must incorporate indication, age, weight, and renal function; misapplication of apixaban dose-reduction criteria and dose–indication mismatches remain common and clinically consequential.
SHOW MORE

Retail pharmacists use a quick checklist to spot risky antithrombotic duplicates, dosing mistakes, OTC interactions, and adherence gaps—helping prevent stroke and bleeding.

This content was independently produced by Pharmacy Times in partnership with Bayer HealthCare.

Antithrombotic therapy is one of the most effective tools for preventing stroke. The 2021 American Heart Association/American Stroke Association (AHA/ASA) secondary stroke prevention guideline recommends antiplatelet or anticoagulant therapy for nearly all patients with prior ischemic stroke or transient ischemic attack without contraindications.1 But that benefit depends on the right drug at the right dose, taken consistently, with every clinician knowing what the patient is actually taking.

That last piece is often where care breaks down. A patient with atrial fibrillation (AF) and prior stroke may see a cardiologist, a neurologist, a primary care provider, and proceduralists, each of whom may start, stop, or adjust therapy. Researchers evaluating a Veterans Affairs antithrombotic stewardship initiative noted that many patients on an anticoagulant plus an antiplatelet may lack an indication for the antiplatelet, and that unclear ownership of antiplatelet management is a recurring barrier to correcting it.2

The community pharmacy is often where all those prescriptions converge. This checklist offers retail pharmacists a practical framework for confirming regimens are appropriate, supporting adherence, and asking the right questions at the counter.

Checklist Item 1: Map the Full Antithrombotic Regimen

  • Review the profile for every anticoagulant and antiplatelet agent, including low-dose aspirin.
  • Ask whether the patient fills prescriptions at another pharmacy or through mail order.
  • Flag duplicate anticoagulants and any anticoagulant-antiplatelet combination without a clear, documented indication.

Why It Matters

The AHA/ASA guideline notes that, with very few exceptions, combining an antiplatelet with an anticoagulant is not typically indicated for secondary stroke prevention.1 In patients with AF or a history of venous thromboembolism, combination therapy has been associated with higher bleeding rates but similar thrombosis rates compared with anticoagulant monotherapy.2 Duplication is also a real-world problem: In a review of apixaban and rivaroxaban orders at a community teaching hospital, duplication with another anticoagulant was the most common reason for pharmacist intervention.3

Ask at the Counter

“Which doctor prescribed this medicine, and do your other doctors know you are taking it?”

Checklist Item 2: Confirm the Dose Fits the Patient

  • Check each direct oral anticoagulant (DOAC) dose against the indication, age, body weight, and renal function.
  • Apply drug-specific dose-reduction criteria; for example, reduced-dose apixaban for AF requires that a patient meet at least 2 of 3 criteria.
  • Ask when the patient last had laboratory work, particularly serum creatinine.

Why It Matters

Inappropriate DOAC dosing is common. In the community teaching hospital review, only 73% of DOAC orders were appropriate; the most common apixaban error involved AF dosing, while the most common rivaroxaban error was a mismatch between dose and indication.3 In 2 geriatric outpatient clinics, 42.7% of patients 65 years and older had DOAC doses inconsistent with FDA labeling, most often reduced-dose apixaban in patients who met only 1 of the 3 dose-reduction criteria.4 Underdosing may leave patients unprotected against stroke, whereas overdosing raises bleeding risk.

Ask at the Counter

“Have you had bloodwork recently? Has anyone mentioned a change in your kidney function or weight?”

Checklist Item 3: Verify Adherence and Persistence

  • Review refill history for gaps or late fills.
  • Ask directly about missed doses, especially with twice-daily regimens.
  • Confirm that any therapy paused for a procedure
    was restarted.
  • Identify barriers such as cost, pill burden, adverse effects, or confusion about dosing.

Why It Matters

Because DOACs have short half-lives, protection wanes quickly when doses are missed. In a French population-based cohort of 76,795 patients with AF newly treated with a DOAC, nonadherence was associated with a 42% higher risk of stroke and a 38% higher risk of death.5 Interruptions are also a coordination risk, as the clinician who pauses therapy before a procedure is often not the one who prescribed it.

Ask at the Counter

“In the past week, how many doses have you missed?” and “Has a doctor or dentist told you to stop this medicine recently? Did you start taking it again?”

Medication synchronization, pill organizers, refill reminders, and co-pay assistance programs can help address the barriers patients identify.

Checklist Item 4: Screen OTC and Supplement Use

  • Ask about nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen.
  • Ask about aspirin-containing OTC products, including some pain relievers and stomach remedies.
  • Ask about dietary and herbal supplements, which patients often do not report to prescribers.

Why It Matters

Patients rarely think of OTC products as “medications,” and prescribers may never learn about them. In a post hoc analysis of the phase 3 RE-LY trial (NCT00262600), which compared dabigatran with warfarin in 18,113 patients with AF, patients who used an NSAID during follow-up had a 68% higher risk of major bleeding, an 81% higher risk of gastrointestinal bleeding, a 50% higher risk of stroke or systemic embolism, and a 64% higher risk of hospitalization compared with those who did not.6

Ask at the Counter

“What do you take for headaches, back pain, or arthritis?” When appropriate, recommend acetaminophen and encourage patients to check with the pharmacist before starting any new OTC product.

Checklist Item 5: Coordinate and Close the Loop

  • When a discrepancy is identified, contact the prescriber responsible for the agent in question.
  • Document the outreach and its outcome.
  • Provide the patient with a single, updated medication list to bring to every appointment.
  • Reconcile the regimen after hospital discharge or any change in care setting.

Why It Matters

The AHA/ASA guideline emphasizes that clinicians should develop care plans collaboratively with patients, incorporating their goals and concerns.1 Investigators studying the Veterans Affairs stewardship initiative likewise identified preventing clinical silos as important to its success.2 Pharmacists are well positioned to bridge those silos.

Ask at the Counter

“Would it help if I called your cardiologist to confirm this?”

Checklist Item 6: Reinforce Warning Signs

  • Review the signs of stroke using the BE FAST mnemonic (balance, eyes, face, arms, speech, time to call 911).
  • Review signs of serious bleeding, such as black or tarry stools, blood in the urine, vomiting blood, unusual bruising, or a sudden severe headache.
  • Encourage patients to carry a wallet card or other identification noting their anticoagulant.
REFERENCES
1. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364-e467. doi:10.1161/STR.0000000000000375
2. Kurlander JE, Robinson CH, Parra D, et al. A qualitative evaluation of barriers and facilitators to a large-scale antithrombotic stewardship intervention in the United States Veterans Healthcare system. Int J Clin Pharm. 2025;47(6):1710-1719. doi:10.1007/s11096-025-01922-2
3. Miele C, Taylor M, Shah A. Assessment of direct oral anticoagulant prescribing and monitoring pre- and post-implementation of a pharmacy protocol at a community teaching hospital. Hosp Pharm. 2017;52(3):207-213. doi:10.1310/hpj5203-207
4. Howerton MA, Suhrie EM, Gennari AS, Jones N, Ruby CM. Evaluation of direct oral anticoagulant dosing and monitoring in two geriatric outpatient clinics. Sr Care Pharm. 2019;34(3):192-205.
5. Gabet A, Chatignoux E, Grave C, et al. Stroke incidence and death in atrial fibrillation patients newly treated with direct oral anticoagulants. Clin Epidemiol. 2021;13:131-140. doi:10.2147/CLEP.S290707
6. Kent AP, Brueckmann M, Fraessdorf M, et al. Concomitant oral anticoagulant and nonsteroidal anti-inflammatory drug therapy in patients with atrial fibrillation. J Am Coll Cardiol. 2018;72(3):255-267. doi:10.1016/j.jacc.2018.04.063

Related to this article